Zimmer Biomet delivered a solid QQ1 2024 performance with revenue of $1.889 billion, up 3.2% reported and 4.4% on a constant-currency basis excluding a ~200 basis point selling-day headwind. Management reaffirmed 2024 guidance of 5%–6% constant-currency revenue growth, with mid-single-digit net earnings growth and free cash flow outpacing earnings growth. The quarter featured meaningful execution across core growth drivers, including ROSA adoption and ongoing momentum in Persona Knee and the cementless Persona OsseoTi platform, supported by a robust product-launch cadence and a widening portfolio in hips with the Z1 triple-taper stem. The company also highlighted a disciplined pricing environment (roughly flat in Q1 vs prior-year erosion of 200–300 bps historically), as well as cost-action programs from the restructuring efforts that contributed to margin expansion and stronger cash flow generation.
Looking ahead, Zimmer Biomet is guiding toward a durable growth path in 2024 driven by a pipeline of more than 40 product introductions planned over the next 24–36 months, along with continued ROSA platform expansion and higher realization from new products. Management emphasized a strategy framed around three priorities—people and culture, operational excellence, and innovation/diversification—positioning the company to monetize portfolio breadth and push WAMGR (weighted-average market growth rate) higher through strategic tuck-ins and selective acquisitions up to ~$2 billion. The QQ1 2024 results set a foundation for a multi-year growth trajectory, albeit with execution risk tied to the ramp of new products and macro conditions.